Antitrust, Infringement Claims Split In Cardizem Suit

Law360, New York (December 17, 2008, 12:00 AM EST) -- A federal judge has agreed to stay parts of discovery and bifurcate the trial in a patent infringement suit over hypertension drug Cardizem, weeks after defendant Sun Pharmaceutical Industries Ltd. introduced a slew of antitrust and patent misuse counterclaims into the suit.

Magistrate Judge Mark Falk of the U.S. District Court for the District of New Jersey signed a consent order Monday approving plaintiff Biovail Laboratories International SRL's requests related to discovery and trial.

According to the order, any response to the pleadings and discovery related...
To view the full article, register now.